Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Two new studies present novel insights into how cancer can control or be controlled by the body's circadian clock and suggest that chronotherapies could have a wider therapeutic impact.
Luet al. identify a potential mechanism driving chondroblastoma and sarcoma development in patients with lysine-to-methionine mutations in histone H3 at position 36 (H3K36M).
A recent article published inNature describes a novel genetic mechanism of immune evasion in a number of cancers that is caused by structural variants (SVs) disrupting the 3′ regulatory region of programmed cell death ligand 1 (PDL1).
This Review discusses the current genetic and functional links between dysregulated and/or mutated RNA splicing factors and cancer, as well as the therapeutic opportunities presented by alterations in alternative splicing in cancer.
The traditionally held belief that neutrophils are inert bystanders in cancer has been challenged by the recent literature. This Review discusses the involvement of neutrophils in cancer initiation and progression, and their potential as biomarkers and therapeutic targets.
This Review describes recent advances in our understanding of tumour-associated myeloid cells in tumour progression and responses to therapy, discussing possible avenues to manipulate these cells in the tumour microenvironment.
This Review discusses PIN1-catalysed prolyl isomerization as a common signalling mechanism to regulate the balance of oncogenes and tumour suppressors. PIN1 inhibitors may be able to restore the balance in cancer cells and cancer stem cells to treat aggressive and drug-resistant tumours.
